Nuvalent (NUVL) Expected to Announce Quarterly Earnings on Thursday

Nuvalent (NASDAQ:NUVL) will likely be announcing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.35) per share and revenue of $0.4860 million for the quarter. Investors may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Friday, May 15, 2026 at 9:30 AM ET.

Nuvalent Stock Performance

Shares of NUVL stock opened at $102.62 on Tuesday. Nuvalent has a one year low of $63.56 and a one year high of $113.01. The company’s 50-day moving average is $101.94 and its 200 day moving average is $102.10. The company has a market capitalization of $8.07 billion, a price-to-earnings ratio of -17.54 and a beta of 1.15.

Insider Activity at Nuvalent

In other news, CFO Alexandra Balcom sold 11,430 shares of the firm’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $105.21, for a total transaction of $1,202,550.30. Following the sale, the chief financial officer owned 85,533 shares of the company’s stock, valued at $8,998,926.93. This trade represents a 11.79% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO James Richard Porter sold 30,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $103.77, for a total transaction of $3,113,100.00. Following the sale, the chief executive officer directly owned 324,879 shares in the company, valued at approximately $33,712,693.83. The trade was a 8.45% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 50,023 shares of company stock worth $5,184,517. 10.20% of the stock is owned by insiders.

Hedge Funds Weigh In On Nuvalent

Several institutional investors have recently made changes to their positions in the business. T. Rowe Price Investment Management Inc. lifted its stake in shares of Nuvalent by 29.3% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 1,319,963 shares of the company’s stock worth $132,776,000 after purchasing an additional 298,727 shares during the period. Invesco Ltd. lifted its stake in shares of Nuvalent by 1,201.4% in the 4th quarter. Invesco Ltd. now owns 439,300 shares of the company’s stock worth $44,189,000 after purchasing an additional 405,543 shares during the period. XTX Topco Ltd bought a new position in shares of Nuvalent in the 4th quarter worth approximately $1,559,000. Ikarian Capital LLC bought a new position in shares of Nuvalent in the 4th quarter worth approximately $5,995,000. Finally, Virtus Investment Advisers LLC lifted its stake in shares of Nuvalent by 73.7% in the 4th quarter. Virtus Investment Advisers LLC now owns 2,538 shares of the company’s stock worth $255,000 after purchasing an additional 1,077 shares during the period. Institutional investors own 97.26% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on NUVL shares. Wells Fargo & Company started coverage on shares of Nuvalent in a research report on Monday, March 30th. They set an “overweight” rating and a $116.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $155.00 price objective on shares of Nuvalent in a research report on Tuesday, April 21st. Cantor Fitzgerald increased their price objective on shares of Nuvalent from $135.00 to $140.00 and gave the company an “overweight” rating in a research report on Friday, February 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Nuvalent in a research report on Tuesday, April 21st. Finally, Wedbush reissued an “outperform” rating and set a $125.00 price objective on shares of Nuvalent in a research report on Wednesday, April 8th. Sixteen analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Nuvalent presently has an average rating of “Moderate Buy” and a consensus price target of $137.25.

About Nuvalent

Nuvalent, Inc (NASDAQ:NUVL) is a clinical-stage precision oncology company focused on the discovery, development and commercialization of targeted therapies for patients with genetically defined cancers. Founded in 2019 and headquartered in San Diego, California, Nuvalent applies structure-guided drug design to develop small molecule inhibitors that address key oncogenic drivers. The company’s research platform integrates insights from cancer biology, medicinal chemistry and translational science to create therapies with differentiated selectivity and potency against validated targets.

Nuvalent’s lead pipeline candidates include NVL-520, a highly selective RET inhibitor designed to minimize off-target effects, and NVL-655, a potent covalent inhibitor targeting KRAS G12D mutations.